

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

NEOTHERAPEUTICS INC
Form 8-K
November 21, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934

November 21, 2002
Date of Report (Date of earliest event reported)

NEOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other Jurisdiction of Incorporation)	000-28782 (Commission File Number)	93-0979187 (IRS Employer Identification Number)
---	---------------------------------------	---

157 Technology Drive Irvine, California (Address of principal executive offices)	92618 (Zip Code)
--	---------------------

(949) 788-6700
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events

On November 21, 2002, NeoTherapeutics, Inc. ("NeoTherapeutics") issued a press release announcing that it had issued 356,956 shares of common stock in a private placement to settle \$628,190.09 in vendor payables. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by this reference.

Item 7(c). Exhibits

Exhibits:

- 4.1 Form of Settlement Agreement and Release
- 4.2 Settlement Agreement and Release dated as of October 22, 2002 by and

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

between NeoTherapeutics, Inc. and Symbion Research International, Inc.

99.1 Press release dated November 21, 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOTHERAPEUTICS, INC.

Date: November 21, 2002

By: /s/ Rajesh C. Shrotriya

Name: Rajesh C. Shrotriya, M.D.
Title: Chairman of the Board,
Chief Executive Officer and President

EXHIBIT INDEX

Exhibits:

-
- 4.1 Form of Settlement Agreement and Release
 - 4.2 Settlement Agreement and Release dated as of October 22, 2002 by and between NeoTherapeutics, Inc. and Symbion Research International, Inc.
 - 99.1 Press release dated November 21, 2002